1Guidelines.Subcommittee of the World Health Organization-International Society of Hypertension(WHO/ISH) Mild Hypertension Liason Committee.1999 World Health Organization-International.Society of Hypertension guidelines for the management of hypertension.J Hypertens,1999,17(2):151-183
2Devereux RB,Alonso DR,Lutas EM,et al.Echocardiographic assessment of left ventricular hypertrophy:comparison to necropsy findings[J].Am J Cardiol,1986,57(6):450-458
3Criscione L,De Gasparo M,Buhlmayer P,et al.Pharmaclogical profile of valsartan:a potent,orally active,nonpeptide antagonist of thangiotensin Ⅱ AT1 receptor subtype.Br J Pharmacol,1993,110(2):761-771
3Brown MJ,Castaigen A, deteeuw PW, et al. Influence of diabetes and type of hypertension on response to antihypertensive treatment[J]. Hypertension, 2000,35 : 1038-1042.
5Michel B. Angiotensin Ⅱ type Ⅰ receptor blockers. Circulation ,2001,103 : 904-912.
6Meredith PA. Optimal dosing characteristics of the angiotensin Ⅱ receptor antagonist temisartan. Am J Cardiol, 1999 , 84:7-12.
7Elliott Wj. Circadian variation in the timing of stroke onset : a meta-analysis. Stroke, 1998,29:992-996.
8Ross R. Atherosclerosis-an inflammatory disease[J]. N Engl J Med, 1999,340(2):115-126.
9Yudkin JS, Kumari M, Humphries SE, et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link[J]?Atherosclerosis,2000,148(2):209-214.
10Skretting G, Gjernes E, Prydz H. Regulation of lecithin:Cholesterol acyltransferase by TGF-beta and interleukin-6[J].Biochem Biophys Acta, 1995,1255(3):267-272.
